Ruth Axer Siegel, MD (Petah Tikva, Israel), Irit Rosenblat, MD (Petah-tikva, Isreal), Anat Loewenstein, MD (Tel Aviv, Israel),* Ludmila Shani, MD (Beer-sheva, Isreal), Adiel Barak, MD (Tel-aviv, Isreal), Tova Lifshitz, MD (Beer-sheva, Isreal), Marina Shneck, MD (Beersheva, Isreal), Amira Springer, MD (Rehovot, Isreal), Ayala Pollack, MD (Rehovot, Israel),
Michaela Goldstein, MD (Tel-aviv, Isreal), Joseph Ferentz, MD (Kfar-saba, Isreal)

PURPOSE:

The PHPTM has previously shown high specificity and sensitivity in detecting newly diagnosed CNV among the population at risk. A new automated version of the PHP, in which technician involvement is not required during test operation, has been developed to create a better standardized test while saving technician time.The aim of this study was to investigate
the ability of PHP-II to detect CNV.

METHODS:

A prospective study was conducted in which consecutive patients with intermediate AMD or CNV underwent eye examination, followed by PHP-II masked examination. The main Inclusion and exclusion criteria included VA of 20/160 or better, age over 55, no other macular disease, no recent surgery or media opacity preventing clear view of the macular
area. Gold standard was based on masked grading of color stereoscopic photographs of suspected intermediate AMD patients and angiograms of suspected CNV patients.

RESULTS:

Of 179 patients, 22 (12%) were excluded due to unreliable test performance. Of 59 eyes with CNV, 45 were identified. Of 98 eyes with intermediate AMD, 88 were identified as having no CNV, yielding a sensitivity of 76% (95% CI [66%-86%]) and a specificity of 90% (95% CI [84%-96%]).

CONCLUSION:

PHP-II can detect recent onset CNV and thus it may be beneficial for monitoring intermediate AMD patients in a more standardized manner while saving technician time.
* Financial interest disclosed